Early trial tests new tablet to help IPF patients breathe

NCT ID NCT07036029

Recruiting now Symptom relief Sponsor: Trevi Therapeutics Source: ClinicalTrials.gov ↗

Summary

This is an early safety study for people with idiopathic pulmonary fibrosis (IPF). Researchers want to see if taking increasing doses of a long-acting tablet called nalbuphine ER is safe and if it affects breathing. The study will involve about 10 participants and will closely monitor their breathing and any side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Medicines Evaluation Unit Ltd.
RECRUITING

Manchester, M23 9QZ, United Kingdom

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC PULMONARY FIBROSIS